Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Payables (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Payables for 4 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Payables rose 14.44% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, up 14.44% year-over-year, with the annual reading at $3.7 million for FY2025, 14.44% up from the prior year.
  • Payables for Q4 2025 was $3.7 million at Day One Biopharmaceuticals, down from $5.8 million in the prior quarter.
  • The five-year high for Payables was $6.4 million in Q2 2024, with the low at $260000.0 in Q4 2022.
  • Average Payables over 4 years is $3.5 million, with a median of $3.6 million recorded in 2023.
  • The sharpest move saw Payables skyrocketed 939.86% in 2023, then plummeted 46.86% in 2025.
  • Over 4 years, Payables stood at $260000.0 in 2022, then soared by 890.77% to $2.6 million in 2023, then increased by 26.63% to $3.3 million in 2024, then rose by 14.44% to $3.7 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $3.7 million, $5.8 million, and $5.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.